Volume 137 · Issue 10 · 2024

临时机械循环支持（tMCS）在管理严重或难治性心源性休克（CS）、提供必要的血流动力学支持以及维持器官灌注数小时至数周甚至数月方面起着关键作用。在过去的十年中，TMC的使用在美国和欧洲国家显著增加。与此同时，在亚洲，构成TMC的新开发概念和设备也取得了快速进展。然而，显然缺乏共识或标准化指南，特别是对于考虑遗传多态性的亚洲人群。为了解决这一知识差距，该领域的八个协会/学会和专家在反复讨论后达成了目前的共识，更具体地说是针对亚洲人口。它全面阐明了常用的tMCS设备、患者选择标准、适应症和禁忌症、临床管理以及植入和断奶的最佳时机。该声明的目标是促进tMCS的规范应用，并在临床实践中做出合理的决策。共识的完整版本可在补充文件http：//links中找到。lww.com/CM9/B883.

Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies. Based on the immunomodulatory capability of CAR-T cells, efforts have turned toward exploring their potential in treating autoimmune diseases. Bibliometric analysis of 210 records from 128 academic journals published by 372 institutions in 40 countries/regions indicates a growing number of publications on CAR-T therapy for autoimmune diseases, covering a range of subtypes such as systemic lupus erythematosus, multiple sclerosis, among others. CAR-T therapy holds promise in mitigating several shortcomings, including the indiscriminate suppression of the immune system by traditional immunosuppressants, and non-sustaining therapeutic levels of monoclonal antibodies due to inherent pharmacokinetic constraints. By persisting and proliferating in vivo, CAR-T cells can offer a tailored and precise therapeutics. This paper reviewed preclinical experiments and clinical trials involving CAR-T and CAR-related therapies in various autoimmune diseases, incorporating innovations well-studied in the field of hematological tumors, aiming to explore a safe and effective therapeutic option for relapsed/refractory autoimmune diseases.

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a well-established oncogenic long non-coding RNA, the higher expression of which is strongly correlated with cancer events such as tumorigenesis, progression, metastasis, drug resistance, and treatment outcome in solid cancers. Recently, a series of studies has highlighted its potential role in hematological malignancies in terms of these events. Similar to solid cancers, MALAT1 can regulate various target genes via sponging and epigenetic mechanisms, but the miRNAs sponged by MALAT1 differ from those identified in solid cancers. In this review, we systematically describe the role and underlying mechanisms of MALAT1 in multiple types of hematological malignancies, including regulation of cell proliferation, metastasis, stress response, and glycolysis. Clinically, MALAT1 expression is related to poor treatment outcome and drug resistance, therefore exhibiting potential prognostic value in multiple myeloma, lymphoma, and leukemia. Finally, we discuss the evaluation of MALAT1 as a novel therapeutic target against cancer in preclinical studies.

Prenatal and postnatal factors may have joint effects on cardiovascular health, and we aimed to assess the joint association of birth weight and ideal cardiovascular health metrics (ICVHMs) prospectively in adulthood with incident cardiovascular disease (CVD).

In the UK Biobank, 227,833 participants with data on ICVHM components and birth weight and without CVD at baseline were included. The ICVHMs included smoking, body mass index, physical activity, diet information, total cholesterol, blood pressure, and hemoglobin A1c. The Cox proportional hazards model was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) in men and women.

Over a median follow-up period of 13.0 years (2,831,236 person-years), we documented 17,477 patients with incident CVD. Compared with participants with birth weights of 2.5-4.0 kg, the HRs (95% CIs) of CVD among those with low birth weights was 1.08 (1.00-1.16) in men and 1.23 (1.16-1.31) in women. The association between having a birth weight <2.5 kg and CVD risk in men was more prominent for those aged <50 years than for those of older age (P for interaction = 0.026). Lower birth weight and non-ideal cardiovascular health metrics were jointly related to an increased risk of CVD. Participants with birth weights <2.5 kg and ICVHMs score 0-1 had the highest risk of incident CVD (HR [95% CI]: 3.93 [3.01-5.13] in men; 4.24 [3.33-5.40] in women). The joint effect (HR [95% CI]: 1.36 [1.17-1.58]) could be decomposed into 24.7% (95% CI: 15.0%-34.4%) for a lower birth weight, 64.7% (95% CI: 56.7%-72.6%) for a lower ICVHM score, and 10.6% (95% CI: 2.7%-18.6%) for their additive interaction in women.

Birth weight and ICVHMs were jointly related to CVD risk. Attaining a normal birth weight and ideal ICVHMs may reduce the risk of CVD, and a simultaneous improvement of both prenatal and postnatal factors could further prevent additional cases in women.

Whether the dynamic weight change is an independent risk factor for mortality remains controversial. This study aimed to examine the association between weight change and risk of all-cause and cause-specific mortality based on the Linxian Nutrition Intervention Trial (NIT) cohort.

Body weight of 21,028 healthy residents of Linxian, Henan province, aged 40-69 years was measured two times from 1986 to 1991. Outcome events were prospectively collected up to 2016. Weight maintenance group (weight change <2 kg) or stable normal weight group was treated as the reference. Cox proportional hazard model was performed to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) to estimate the risk of mortality.

A total of 21,028 subjects were included in the final analysis. Compared with the weight maintenance group, subjects with weight loss ≥2 kg had an increased risk of death from all-cause (HR_All-cause = 1.14, 95% CI: 1.09-1.19, P <0.001), cancer (HR_Cancer = 1.12, 95% CI: 1.03-1.21, P = 0.009), and heart disease (HR_{Heart diseases} = 1.21, 95% CI: 1.11-1.31, P <0.001), whereas subjects with weight gain ≥5 kg had 11% (HR_Cancer = 0.89, 95% CI: 0.79-0.99, P = 0.033) lower risk of cancer mortality and 23% higher risk of stroke mortality (HR_Stroke = 1.23,95% CI: 1.12-1.34, P <0.001). For the change of weight status, both going from overweight to normal weight and becoming underweight within 5 years could increase the risk of total death (HR_{Overweight to normal} = 1.18, 95% CI: 1.09-1.27; HR_{Becoming underweight} = 1.35, 95% CI: 1.25-1.46) and cancer death (HR_{Overweight to normal} = 1.20, 95% CI: 1.04-1.39; HR_{Becoming underweight} = 1.44, 95% CI: 1.24-1.67), while stable overweight could increase the risk of total death (HR_{Stable overweight} = 1.11, 95% CI: 1.05-1.17) and death from stroke (HR_{Stable overweight} = 1.44, 95% CI: 1.33-1.56). Interaction effects were observed between age and weight change on cancer mortality, as well as between baseline BMI and weight change on all-cause, heart disease, and stroke mortality (all P_interaction <0.01).

Weight loss was associated with an increased risk of all-cause, cancer, and heart disease mortality, whereas excessive weight gain and stable overweight were associated with a higher risk of stroke mortality. Efforts of weight management should be taken to improve health status.

https://classic.clinicaltrials.gov/, NCT00342654.

Influenza and pneumococcal vaccination are a priority in patients with chronic obstructive pulmonary disease (COPD). However, limited information is available on vaccination coverage among patients with acute exacerbations of COPD (AECOPD) in China. This study aimed to determine the rates and associated factors of influenza and pneumococcal vaccination in patients hospitalized with AECOPD.

Baseline data from a national, multicenter, hospital-based study that included adult inpatients with AECOPD between 2017 and 2021 were analyzed. The outcomes of interest were the influenza vaccination in the past year and the pneumococcal vaccination in the past 5 years. To ensure national representativeness, rates were weighted according to the distribution of hospital levels and types enrolled in this study. Multivariable Poisson regression based on mixed-effects models were used to determine the associated factors. The independent variables included the region and hospital features where the participants were located, sociodemographic characteristics (age, sex, rural/urban residence, education, etc.), and clinical indicators (COPD disease history, lung function parameters, comorbidities, etc.). The treatment profiles of the vaccinated and unvaccinated participants were compared.

Of 6949 eligible participants, the weighted rates of influenza/pneumococcal, influenza, and pneumococcal vaccination were 2.72% (95% confidence interval [CI]: 2.34%-3.10%), 2.09% (95% CI: 1.76%-2.43%), and 1.25% (95% CI: 0.99%-1.51%), respectively. In multivariable models, age ≥60 years (60-69 years, odds ratio [OR]: 1.90, 95% CI: 1.11-3.25; ≥80 years, OR: 2.00, 95% CI: 1.06-3.78), geographical regions (Northern China relative to Eastern China, OR: 5.09, 95% CI: 1.96-13.21), urban residence (OR: 1.69, 95% CI: 1.07-2.66), a higher education level (junior high school, OR: 1.77, 95% CI: 1.21-2.58; senior high school or above, OR: 2.61, 95% CI: 1.69-4.03), former smoking (OR: 1.79, 95% CI: 1.15-2.79), and regular inhaled medication treatment (OR: 3.28, 95% CI: 2.29-4.70) were positively associated with vaccination. Patients who had experienced severe exacerbations in the past year were less likely to be vaccinated (OR: 0.65, 95% CI: 0.45-0.96). Compared with unvaccinated participants, vaccinated participants adhered better to pharmacological and non-pharmacological treatment.

Influenza and pneumococcal vaccination coverage are extremely low. Urgent measures are necessary to increase vaccination coverage among inpatients with AECOPD in China.

There is a need for effective and safe therapies for psoriasis that provide sustained benefits. The aim of this study was to assess the efficacy and safety of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, for treating moderate-to-severe plaque psoriasis in Chinese patients.

In this multi-center, double-blind, phase III trial, patients with moderate-to-severe plaque psoriasis were enrolled and randomly assigned (1:1) to receive subcutaneous tildrakizumab 100 mg or placebo at weeks 0 and 4. Patients initially assigned to placebo were switched to receive tildrakizumab at weeks 12, 16, and every 12 weeks thereafter. Patients in the tildrakizumab group continued with tildrakizumab at week 16, and every 12 weeks until week 52. The primary endpoint was the Psoriasis Area and Severity Index (PASI 75) response rate at week 12.

At week 12, tildrakizumab demonstrated significantly higher PASI 75 response rates (66.4% [73/110] vs. 12.7% [14/110]; difference, 51.4% [95% confidence interval (CI), 40.72, 62.13]; P <0.001) and Physician’s Global Assessment (60.9% [67/110] vs. 10.0% [11/110]; difference, 49.1% [95% CI, 38.64, 59.62]; P <0.001) compared to placebo. PASI 75 response continued to improve over time in both tildrakizumab and placebo-switching to tildrakizumab groups, reaching maximal efficacy after 28 weeks (86.8% [92/106] vs. 82.4% [89/108]) and maintained up to 52 weeks (91.3% [95/104] vs. 87.4% [90/103]). Most treatment-emergent adverse events were mild and not related to tildrakizumab.

Tildrakizumab demonstrated durable efficacy through week 52 and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.

ClinicalTrials.gov, NCT05108766.

Growth retardation is a common complication of chronic kidney disease in children, which can be partially relieved after renal transplantation. This study aimed to develop and validate a predictive model for growth patterns of children with end-stage renal disease (ESRD) after kidney transplantation using machine learning algorithms based on genomic and clinical variables.

A retrospective cohort of 110 children who received kidney transplants between May 2013 and September 2021 at the First Affiliated Hospital of Zhengzhou University were recruited for whole-exome sequencing (WES), and another 39 children who underwent transplant from October 2021 to March 2022 were enrolled for external validation. Based on previous studies, we comprehensively collected 729 height-related single-nucleotide polymorphisms (SNPs) in exon regions. Seven machine learning algorithms and 10-fold cross-validation analysis were employed for model construction.

The 110 children were divided into two groups according to change in height-for-age Z-score. After univariate analysis, age and 19 SNPs were incorporated into the model and validated. The random forest model showed the best prediction efficacy with an accuracy of 0.8125 and an area under curve (AUC) of 0.924, and also performed well in the external validation cohort (accuracy, 0.7949; AUC, 0.796).

A model with good performance for predicting post-transplant growth patterns in children based on SNPs and clinical variables was constructed and validated using machine learning algorithms. The model is expected to guide clinicians in the management of children after renal transplantation, including the use of growth hormone, glucocorticoid withdrawal, and nutritional supplementation, to alleviate growth retardation in children with ESRD.

With an increasing number of patients with hematological malignancies being treated with umbilical cord blood transplantation (UCBT), the correlation between immune reconstitution (IR) after UCBT and graft-versus-host disease (GVHD) has been reported successively, but reports on double-negative T (DNT) cell reconstitution and its association with acute GVHD (aGVHD) after UCBT are lacking.

A population-based observational study was conducted among 131 patients with hematological malignancies who underwent single-unit UCBT as their first transplant at the Department of Hematology, the First Affiliated Hospital of USTC, between August 2018 and June 2021. IR differences were compared between the patients with and without aGVHD.

The absolute number of DNT cells in the healthy Chinese population was 109 (70-157)/μL, accounting for 5.82 (3.98-8.19)% of lymphocytes. DNT cells showed delayed recovery and could not reach their normal levels even one year after transplantation. Importantly, the absolute number and percentage of DNT cells were significantly higher in UCBT patients without aGVHD than in those with aGVHD within one year (F = 4.684, P = 0.039 and F = 5.583, P = 0.026, respectively). In addition, the number of DNT cells in the first month after transplantation decreased significantly with the degree of aGVHD increased, and faster DNT cell reconstitution in the first month after UCBT was an independent protective factor for aGVHD (HR = 0.46, 95% confidence interval [CI]: 0.23-0.93; P = 0.031).

Compared to the number of DNT cells in Chinese healthy people, the reconstitution of DNT cells in adults with hematological malignancies after UCBT was slow. In addition, the faster reconstitution of DNT cells in the early stage after transplantation was associated with a lower incidence of aGVHD.

Ebstein’s anomaly (EA) is a rare and complex congenital heart anomaly, and the effect of surgical treatment is not ideal. This study aims to introduce our experience in management strategies, surgical techniques, and operative indications for patients with Ebstein’s anomaly.

A retrospective study of 258 operations was performed in 253 patients by the same cardiac surgeon in The First Hospital of Tsinghua University between March 2004 and January 2020. 32 patients had previously received cardiac surgery in other hospitals. The clinical data including diagnosis, operative indications, techniques, pathological changes, and survival rates were collected and analyzed.

Anatomical correction was performed in 203 (78.7%) operations, 1½ ventricle repair in 38 (14.7%) operations, tricuspid valve repair only in four operations (1.6%), tricuspid valve replacement in ten (3.9%), total cavopulmonary connection (TCPC) in two (0.8%), and Glenn operation in one operation (0.4%). Reoperation was performed in five patients (2.0%) during hospitalization. Among them, tricuspid valve replacement was performed in one patient, 1½ ventricle repair in two patients, and tricuspid valve annulus reinforcement in two patients. Five patients died with an early mortality rate of 2.0%. Complete atrioventricular conduction block was complicated in one patient (0.4%). A total of 244 patients was followed up (four in the 253 patients lost) with a duration of 3.0-168.0 (87.6 ± 38.4) months. Cardiac function of 244 patients improved significantly with mean New York Heart Association (NYHA) functional class recovery from 3.5 to 1.1. The mean grade of tricuspid valve regurgitation improved from 3.6 to 1.5. Three late deaths (1.2%) occurred. The survival rates at five and ten years after surgery were 98.6% and 98.2%, respectively. Reoperation was performed in five patients (2.0%) during the follow-up period.

Based on our management strategies and operative principles and techniques, anatomical correction of EA is capable of achieving excellent long-term results, and low rates of TCPC, 1½ ventricle repair and valvular replacement.

尿流术是一种用于记录排尿量（VV）和流速的尿流测量技术，可帮助临床医生客观评价下尿路功能。目前，很少有尿流率研究关注女性人群，^[1]尤其是尿流曲线标准分析。因此，我们试图为中国女性建立可靠的尿流参考值和诺模图，并评估尿流模式与人口统计学数据之间的关系。

致编辑：静脉-动脉体外膜肺氧合（VA-ECMO）已被用作等待心脏移植（HTx）的晚期心力衰竭（AdHF）患者的桥梁。发达国家报道的多项研究证实了VA-ECMO在桥接至左心室辅助装置（LVAD）或HTx方面的优势，具有稳定病情和提高患者进一步治疗的可能性。^[1,2,3]体外生命支持组织（ELSO）的最新数据^[4]表明用作桥梁的ECMO在十年中增加了20.5%。然而，迄今为止，关于VA-ECMO在中国大陆的桥梁经验的研究很少。

致编辑失明和视力丧失（BVL）是一个日益严重的问题，影响着不断扩大的全球人口。^[1]在全球范围内，大约40%的人口依靠燃烧固体燃料来做饭和取暖。家庭空气污染（HAP）主要来自用于烹饪的固体燃料的不完全燃烧。如今，HAP对人类眼睛健康的不利影响已经上升为环境、眼科和公共健康的突出问题。^[2]全面了解HAP引起的BVL的负担和时间趋势是卫生项目规划的重要基础。

致编辑：肉类是蛋白质的重要来源，大致可分为红肉和白肉。白肉，包括家禽、鱼虾等海鲜和爬行动物等。，其特征是未煮熟时颜色较浅。红肉基本上是哺乳动物肉，包括家畜肉，如猪肉、牛肉、羊肉，以及某些地区的野生动物肉，如袋鼠、海豹、鲸鱼。由于骨骼肌中存在肌红蛋白，未煮熟的哺乳动物肉呈现红色。哺乳动物肉过敏的临床表现包括两种类型的过敏反应，即速发型和延迟型，尽管两者都是由免疫球蛋白E(IgE)介导的。速发型超敏反应表现为摄入红肉后不久出现的过敏症状，主要由血清白蛋白和免疫球蛋白触发，血清白蛋白和免疫球蛋白是主要的过敏原成分。这是食物过敏的典型模式。迟发型超敏反应的特征是在摄入红肉后2-6小时过敏症状延迟发作，并由寡糖α-gal特异性IgE介导，这是最近发现的食物过敏模式。^[1]

致编辑：慢性阻塞性肺病（COPD）是一个全球性的公共卫生挑战，目前没有有效的治疗方法，影响全球超过3亿人。需要全面了解本病的发病机制。最近，铁下垂（一种由铁依赖性脂质过氧化驱动的细胞死亡形式）与COPD的发病机制有关。^[1]多种信号通路，如谷胱甘肽过氧化物酶4(GPX4）、铁下垂抑制蛋白1(FSP1）和四氢生物蝶呤依赖性通路，以及铁代谢，参与调节铁下垂^[2,3][图1A].在这里，我们全面概述了了解铁下垂在COPD中的作用的最新进展，强调了针对铁下垂治疗该疾病的潜在治疗策略。

致编辑：儿科和青少年妇科（PAG）是妇科的一个专业分支，专注于妇女从婴儿期到青春期的生殖健康问题。^[1]1939年，匈牙利Dobszay首先建立了新的分支机构。此后，PAG学科开始发展，并在近80年的时间里逐渐成熟。虽然PAG在西方国家取得了重大发展，但在解决患有妇科疾病的儿童和青少年的具体健康问题方面，仍有大量未得到满足的需求。在PAG学科尚处于起步阶段的中国，这种情况变得更加严峻。年轻女性在妇科领域经历的疾病有其自身的特殊性。^[1]此外，PAG与各种医学学科都有联系，尤其是外科。调查PAG外科疾病的住院疾病谱、患病率和临床特征具有重要的临床意义，但在中国或其他国家，以前没有研究解决这一问题。因此，本研究回顾性分析了2010年1月至2022年5月在北京大学第一医院（PKUFH）接受外科治疗的512例0-18岁PAG住院患者的临床数据，以全面概述PAG外科疾病的住院疾病谱和临床特征，旨在为未来的临床工作提供管理建议和证据支持。该研究由PKUFH机构审查委员会批准（第2022[593]号），由于该研究的回顾性，放弃了知情同意。非正态分布的定量变量显示为中位数（Q1，Q3），分类变量显示为计数和百分比。使用卡方检验和Fisher精确检验进行比较检验。

致编辑：5q脊髓性肌萎缩症（5qSMA）是一种常染色体隐性神经肌肉疾病，由缺乏由SMN1基因，位于5q11.2-q13.3。^[1]发病率为活产的1/10000-1/6000，我国突变携带率为1/42。^[1]根据曾经达到的运动里程碑，脊髓性肌萎缩症（SMA）主要分为四种亚型：SMA I型、II型、III型和IV型。I-III型好发于儿童，^[1]这通常导致进行性肌肉萎缩和虚弱以及多系统功能障碍，包括营养和代谢问题。^[2]患有SMA的儿童可能有隐藏的营养和脂质失衡，尽管身体外观和人体测量正常，因此很难早期发现和干预。很少有研究阐明SMA患者的营养状况和脂质代谢，^[2]尤其是在亚洲，那里的SMA患者数量可能是世界上最高的。为了制定有针对性的营养管理策略，本研究旨在基于中国一项基于医院的病例对照研究，调查SMA儿童的营养状况和血脂特征。本研究由浙江大学医学院附属儿童医院伦理委员会批准（编号：2019-IRB-171）。获得了所有患者及其法定监护人的书面知情同意书。

致编辑：在年轻人群中，过早冠状动脉疾病（CAD）的全球负担正在增加。过早CAD通常是指老年男性和女性发生阻塞性冠状动脉粥样硬化血栓性病变<55岁及<65岁，尤其是老年人<45年了。^[1]尽管老年人的发病率在下降，但年轻人群中CAD的发病率保持稳定或增加。早期CAD患者的长期预后较差，经历高复发率的缺血事件，快速进展为多血管疾病，并且经常过早死亡。^[1]因此，确定不同于年龄相关性CAD的早产CAD的潜在原因并通过精确的诊断和治疗改善患者结局至关重要。

致编辑：射血分数保留的心力衰竭（HFpEF）是一种以舒张功能受损为特征的临床实体。直到最近，很少有研究直接评估容量状态如何影响HFpEF患者未来的心脏事件。支持螺内酯在HFpEF中应用的证据主要来源于一项醛固酮拮抗剂治疗保留心功能的心力衰竭（TOPCAT）试验。尽管试验的初步分析得出了中性结果，但亚组和随后的事后分析证实了其在选定患者组中的疗效，表明确定受益于螺内酯治疗的潜在患者亚组是重要的。^[1]缺乏关于充血状态对螺内酯治疗HFpEF疗效影响的数据。体积状态的综合评估在某种程度上可能会很复杂。通过体征确定临床上明显的充血被期望是简单和实用的。然而，并非所有充血的体征都同时存在于患者体内，这需要在临床实践中进行综合判断。潜在类分析（Latent class analysis，LCA）是一种可以实现这一目标的聚类统计方法。它已被用于识别具有某些特征的人群中潜在的不同亚组。在这项研究中，通过利用TOPCAT试验的数据，我们通过选择LCA的典型充血体征确定了具有临床明显充血的HFpEF患者亚组，并探讨了基线明显充血和时间更新的充血状态的预后意义及其与螺内酯治疗的相互作用。

致编辑：原发性干燥综合征（pSS）是一种以外分泌腺（主要是唾液腺和泪腺）受累为特征的多系统自身免疫性疾病，导致口干症和眼干症。^[1]pSS的病程相对缓慢，但pSS患者患总体癌症的风险较高，包括恶性淋巴瘤（ML）。^[2]众所周知，与健康对照组相比，pSS患者的全因死亡率没有增加。尽管如此，继发性淋巴增生性疾病是死亡率过高的重要原因。

致编辑：腹主动脉瘤（AAA）是一种危及生命的血管疾病。当AAA的最大直径达到男性5.5 cm和女性5.0 cm的阈值时，或者当AAA经历大于1.0 cm/年的快速扩张时，通常建议进行手术干预。^[1]AAA修复后的生存率受多种因素影响，独立预后因素的识别和准确预测模型的开发对于最佳治疗计划、咨询和术后随访至关重要。尽管已经开发了几种准确性不同的评分系统来预测AAA破裂患者干预后的死亡风险，但关于其性能的相互矛盾的结果已经发表。^[2,3]理想情况下，预测模型应该是用户友好的和广泛适用的，仅基于几个容易获得的术前参数提供快速和可靠的结果估计。遗憾的是，辅助临床医生估计动脉瘤修复后一般AAA患者长期死亡率的临床模型数量有限，也缺乏关注中国人群的评分。因此，本研究的目的是探索影响接受AAA修复患者长期死亡风险的潜在生物标志物，并建立一个易于使用和实用的中国人群AAA修复后全因死亡率的术前风险预测模型。该模型可能有助于根据AAA患者的预测预期寿命将其分为不同的组，为决策提供信息，并在临床试验中实施医疗干预。